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ABSTRACT
Betaine is distributed widely in animals, plants, and microorganisms and rich dietary sources include seafood, especially marine invertebrates. Betaine 
is N-trimethylated amino acid called as glycine betaine. It is a by-product. Betaine aldehyde is produced when choline dehydrogenase acts on choline, 
then betaine aldehyde is oxidized to form betaine by aldehyde dehydrogenase. Metabolic derived betaines possess various functions in our body in 
which they act as methyl donor which helps in liver function, detoxication, and cellular functions. It plays an important role in fat metabolism. Recent 
research found that betaine can convert homocysteine to cysteine thus they prevent heart disease. Choline is oxidized to betaine in liver and kidney. 
Intracellular betaine serves as an osmolyte that regulates cell volume and tissue integrity. Betaine not only plays as an osmolyte but also play a major 
role in the protection of the liver and other tissues. Consequently, it has been proposed that betaine has significant nutrient for prevention of chronic 
disease. Betaine has been shown to protect internal organs, improve vascular risk factors, and enhance performance. Databases of betaine content in 
food are being developed for correlation with population health studies. This review focuses on the aspects of wide research field with emphasis on a 
recent data relevant to various human diseases.
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INTRODUCTION
Betaine was early identified in the sugar beets (beta vulgaris) juice in 
the 19th century and was commonly found in several other organisms. 
The physiologic action of betaine is that it performs as an organic 
osmolyte to protect cells under stress or as a catabolic source of methyl 
groups through transmethylation in many biochemical pathways [1]. 
The significant role of betaine in plants and microorganisms is to 
protect cells against osmotic inactivation. Betaine (glycine betaine 
or N, N, N-trimethylglycine) is obtained from the diet or from its 
metabolic precursor choline [2]. Betaine is a major tissue osmolyte 
and plays a vital role in the metabolism of homocysteine, with betaine 
homocysteine methyltransferase (BHMT) catalyzing the remethylation 
of homocysteine to methionine.
Betaine is also known as glycine betaine, betaine anhydrous, or 
trimethylglycine (TMG) is a compound in the body and is involved 
in several functions such as liver function, cellular reproduction, 
and helping make carnitine. It also helps the body in homocysteine 
metabolism. Betaine is used to treat a genetic condition where too 
much homocysteine builds up in the body which is approved by the US 
Food and Drug Administration.
BETAINE STRUCTURE
TMG is an N-trimethylated amino acid and its quaternary ammonium 
exists as the zwitterion at neutral pH. Strong acids such as hydrochloric 
acid convert TMG to various salts, with HCl yielding betaine 
hydrochloride.
(CH3)3N+CH2CO2 + HCl → [(CH3)3N+CH2CO2H]Cl−
Demethylation of TMG gives dimethylglycine. Degradation of TMG 
yields trimethylamine, the scent of putrefying fish (Fig. 1).
Synthesis of betaine
Humans and animals can synthesize glycine betaine in a two-step 
process. The first step is the oxidation of choline to betaine aldehyde 
by the enzyme choline dehydrogenase. In the second step, betaine 
aldehyde is further oxidises with the enzyme betaine aldehyde 
dehydrogenase to produce betaine. An important major role of betaine 
in humans is to serve as a cofactor in methylation reactions, which 
occurs in all mammal cells.
Other names of betaine
2(N,N,N-trimethyl)ammonium-acetate, betaína anhidra, bétaïne 
anhydre, betaine anhydrous, bétaïne de glycine, bétaïne de glycocoll, 
cystadane, glycine betaine, glycocoll betaine, glycylbetaine, lycine, 
oxyneurine, tmg.
Sources of betaine
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APPLICATIONS AND USES OF BETAINE
Betaine is a natural alkaloid widely used as nutrition supplement 
in animal feed. As an essential nutrient betaine can be used in a 
wide variety of industries including food production, beverage, 
pharmaceutical, cosmetics, agriculture, animal feed, and various other 
industries.
• Betaine is used as natural preservative in food industry.
• Betaine is used in beverage industries.
• Betaine is used as active ingredient in pharmaceutical industries. It 
is used as medicine in various diseases.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i10.18075
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• Betaine acts as cleansing and water retaining agent in cosmetics and 
also in shampoo, soap, and toothpaste.
• In cattle and poultry feed betaine is used to improve the growth.
BETAINE IN THE TREATMENT OF CANCER
In recent years, many articles revealed that the growth of cancer 
cells can be inhibited by betaine in vitro. The primary biochemical 
function executed by betaine is the transfer of one-carbon moieties to 
maintain normal DNA methylation pattern in the body. Stabling of their 
methylation patterns is done by regulating the expression of proto-
oncogenes and tumor suppressors; betaine exerts its anticancer action.
LUNG CANCER
About 28% of global cancer-related deaths and 15% of other diagnosed 
cancer deaths are caused by Lung cancer. Abnormal changes in DNA 
methylation leads to the activation of certain protooncogenes, such as 
c-Myc, and also to the inactivation of certain tumor suppressors, such as 
p16 [3] which can be observed in the development and progression of 
cancer. Some reports imply that certain dietary components affect the 
process of carcinogenesis, through DNA methylation. In fact, it has been 
shown that folate, as methyl group donors, riboflavin, vitamin B6, and 
vitamin B12, acts as cofactors in one-carbon metabolism are involved 
with DNA synthesis and DNA methylation and hence, they play a vital 
role in carcinogenesis and cancer risk; DNA global hypomethylation 
is associated with lung cancer. Researches shown that genetic code 
mechanism itself controls the methylation of DNA [4]. Betaine (B) 
maintains normal DNA methylation patterns [5] since it acts as a major 
methyl donor.
BETAINE IN LUNG CANCER
Humans obtain betaine from dietary choline. Choline is oxidized 
into betaine in a two-step enzyme-dependent reaction in liver and 
kidney. Betaine is involved in the synthesis of methionine, which 
acts as a major supplier of cellular cysteine through transsulfuration 
pathway for the synthesis of reduced glutathione which protects the 
cell from reactive oxygen species [6]. In choline-mediated one-carbon 
metabolism, signaling functions, cell membrane structural integrity, 
and neurotransmitter synthesis betaine plays a major role. Betaine is 
proved to be safe at a daily intake of dosage 9-15 g [6] which should 
not exceed. Betaine is nontoxic at all doses (0-5% of the diet) which has 
determined from subacute and subchronic rat studies.
They revealed that in vitro 4% betaine could effectively decrease 
the viability of A549 lung cancer cells, which shows better effect in 
combination with C-PC. New anticancer drugs are developed with 
therapeutic target of the cancer cell cycle disturbances [7]. In cell 
proliferation, differentiation, and apoptosis cell cycle regulation betaine 
plays a vital role. The present investigation has been reported that the 
dysfunction of cell cycle regulation appears to be closely connected 
to tumor onset and development. Results from in vitro studies shown 
that there is some kind of interaction between C-PC and betaine that 
is still unknown. Since betaine transporters belong to the SLC36 group 
of proton-coupled amino acid symporters that are pH sensitive [8], it is 
possible that C-PC as a cysteine/methionine-rich protein [8] influences 
the uptake of betaine into the cells by adjusting the pH through the 
acid-base properties of its amino acid side-chains. The decrease of 
CPC fluorescence inside the cells when combined with betaine may be 
explained by C-PC slightly changing the conformation after changing 
its amino acid charge by donating/accepting H+ ions. Furthermore, it 
might be possible that C-PC interacts with betaine itself since betaine 
is an amino acid-like compound, which can change its charge and 
transport over the cell membrane or interactions inside the cell.
Many studies proved that betaine and C-PC are easily applicable and 
powerful inhibitors of the A549 cell line growth. Thus, this combined 
treatment proved to be an effective inhibitor of the growth of A549 cells 
by preventing the cell cycle progression, reducing the cell viability, or 
enhancing the proapoptotic pathways.
LIVER CANCER
Liver cancer is commonly seen types of malignancy, especially in Asia 
and Africa, and it is the second most common cause of cancer death 
in China [9]. The progress of liver cancer is a multistep process of 
genetic alterations, involving the activation of proto-oncogenes and the 
inactivation of tumor suppressors, which lead to a continuous increase 
of uncontrolled cellular proliferation. Therefore, abnormal expression 
of related genes plays a crucial role in carcinogenesis. Transcription 
factor involved in regulating cell proliferation, differentiation, and 
apoptosis [10] is encoded by c-myc proto-oncogene. Abnormal changes 
in mRNA expression and DNA methylation of p16 and c-myc are 
therefore, the two important stimulatory factors in the development of 
liver cancer.
BETAINE IN LIVER CANCER
An important biochemical function of betaine is to transfer one-carbon 
moieties to maintain DNA methylation pattern in the body [11]. Thus, 
the betaine involved in preventing the liver cancer through regulating 
the expression of proto-oncogenes and tumor suppressors by stabling 
their mythylation patterns. Another major role of betaine is one-carbon 
metabolism which is important for liver function. Hepatic betaine is also 
act as a methyl donor. The expression of BHMT1 mRNA is at least 50 
fold more abundant in mouse liver than any other tissue. A disturbance 
of hepatic one-carbon metabolism can lead to liver diseases including 
fatty liver, steatosis and hepatocellular carcinoma. Betaine contributes 
significantly to the transmethylation of homocysteine to methionine 
because the BHMT1 pathway is the most important route for the 
removal of homocysteine (cardiovascular risk factor) and catabolism 
of betaine.
CERVICAL CANCER
Cervical cancer is the third most common type of malignancy and the 
fourth leading cause of cancer-related mortality in women worldwide, 
accounting for 9% (529,800) of the total new cases and 8% (275,100) 
of the total cancer deaths among females in 2008 [12]. HeLa cell was 
the first human cell line established in culture, originated from a 
biopsy of cervical cancer tumor of a patient named Henrietta Lacks in 
1951. Much of our understanding about fundamental cell physiology 
and cancer biology is due to HeLa cell research. Recently, two Nobel 
prizes have been awarded for research involving HeLa cells, namely, 
the link between human papillomavirus and cervical cancer [13]. 
Cervical cancer is usually a slowly developing neoplasm, and screening 
methods such as the Pap smear and HPV DNA test are available for 
early detection of precancer and cancer, hence, there is a substantiable 
scope for chemoprevention [14]. Apart from nutrients, antihormones, 
Fig. 1: IUPAC name: 2-trimethylammonioacetate
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vitamin A analogues, and COX-2 inhibitors, extracts of medicinal plants 
also have shown in vivo and in vitro anticancer activity and have been 
evaluated for secondary chemoprevention or as complementary 
therapy in advanced cancer [15,16].
BETAINE IN CERVICAL CANCER
A successful anticancer compound should kill or incapacitate cancer 
cells without causing excessive damage to normal cells. HeLa cells 
treated with the betaine showed a dose-dependent decrease in 
superoxide dismutase activities. On treatment with increasing 
concentration of betaine, there was a significantly rise in the mRNA 
and protein expression of Bcl-2 in a time dependent manner in HeLa 
cells [7]. Another three important genes involved in cell cycle regulation 
and cell apoptosis, Bax, p53, and Caspase 3, are all overexpressed 
in Hela cells. Moreover, the expression of Bax, p53, and Caspase 3 
significantly increased in these cells after treatment with increasing 
concentration of betaine compared to untreated cells. The results 
indicated that upregulation of cyclin D1 expression promotes G1 phase 
arrest in Hela cells, and the p53-mediated cell cycle regulation pathway 
was dependent on cyclin D1. Betaine treatment in low dose groups 
enhanced cellular Bcl-2 expression and the Bcl-2/Bax ratio, thereby 
reversing drug resistance and inhibiting cell apoptosis. However, 
betaine in high concentration may cause damage to HeLa directly, and 
trigger apoptosis through Caspase 3 signaling pathway and further 
promote necrosis. Thus, treatment of betaine in high dose could inhibit 
the proliferation of drug-resistant cervical cancer cells and promote cell 
apoptosis (Table 1).
HOMOCYSTEINEMIA
Persons with an elevated serum homocysteine concentration are 
termed as hyperhomocystinemia or homocystinemia, and they have 
high risks of getting cardiovascular disease, stroke, Alzheimer disease, 
dementia, neural tube defects, and also some metabolic disorders [17]. 
An elevated level of fasting serum homocysteine and an elevated 
response of homocysteine after methionine loading (postmethionine) 
are independent risk factors for cardiovascular disease [18].
Betaine can improve both risk factors, and in humans with cardiovascular 
disease, there is a significant inverse relation between plasma betaine 
and homocysteine concentrations in fasting [19] and postmethionine 
states. Cardiovascular disease risk in healthy humans can be overcome by 
intake of betaine-rich diet. Elevated serum homocysteine is caused by an 
imbalance in the methionine cycle because of either genetic or nongenetic 
(e.g., Nutritional) defects that result in homocysteinemia. Parallel 
increase in intracellular S-adenosylhomocysteine (SAH) is the result 
of chronic elevation of homocysteine and this, in combination with the 
S-adenosylmethionine (SAM):SAH ratio is predictive of cellular methylation 
status [20]. The activation of defective (mutant) enzyme activity with the 
relevant cofactor or its precursor (e.g., Folic acid or vitamins B-12 or B-6) is 
the treatment or preventive measures given to the patients, and it is based 
on the cause and severity of the defect. An alternative treatment is that 
pharmacologic doses of betaine or folic acid have been used to enhance the 
alternative pathway of homocysteine turnover.
Homocystinuria
Accumulation of homocysteine in the blood and urine leads to an 
inherited disorder namely homocystinuria. Homocystinuria patients 
usually lack a functioning cystathionine B-synthase, an enzyme which 
is responsible for breaking down of homocysteine. Due to a defect of 
this enzyme, an excess amount of homocysteine accumulates in the 
body which can be toxic at high levels. The symptoms of the disease 
usually noticed in the first few days of life and long-term consequences 
include learning disabilities, brittle bones, problems with vision and 
blood disorders can also be occurred. Homocystinuria is a long-term 
debilitating and life-threatening disease which may lead to blood 
clotting and heart problems and blood vessels and is associated with 
poor overall survival.
DEFICIENCY
Homocystinuria can be caused by a deficiency of cystathionine 
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• Fair brittle hair
• Thin skin
• Fatty changes in liver
• Myopathy.
BETAINE TREATMENT
Cystathionine is formed by the condensation of homocysteine and 
serine by CBS. Vitamin B-6 acts as a cofactor for CBS, and 50% of 
patients with homocystinuria are responsive to vitamin B-6 therapy. It 
is difficult to treat Homocystinuria that is not responsive to vitamin B-6, 
but betaine, either alone or combined with other therapies, improves 
clinical symptoms, reduces homocysteine, and increases plasma 
methionine, serine, and cysteine concentrations [21]. Homocysteine 
gets accumulated in the central nervous system in CBS deficiency 
and may play a role in neurologic complications. Betaine treatment 
in children moderately lowers homocysteine in cerebrospinal fluid 
and increases serine and SAM concentrations [21]. Studies on 
Table 1: Betaine treatment in different cancer types
Disease Clinical changes Betaine treatment
Lung cancer Abnormal changes in DNA methylation Betaine maintains DNA methylation patterns: Acts as major methyl 
donor
Liver cancer Genetic alterations involve activation of proto-oncogenes 
inactivation of tumor suppressors
Regulation of expression of proto-oncogenes and tumor 
suppressors stabling the methylation patterns
Cervical cancer Slowly developing neoplasm Betaine in high concentration trigger apoptosis through Caspase 3 
signaling pathway
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MTHFR deficiency [22] showed that betaine improves homocysteine 
methylation, lowers plasma homocysteine, normalizes very low plasma 
methionine, elevates SAM, and leads to clinical improvement.
MILD HOMOCYSTEINEMIA
Mild homocysteinemia is mostly seen than homocystinuria and 
is characterized by mildly elevated fasting or postmethionine 
homocysteine concentrations. Pooled data from many studies showed 
that mild homocysteinemia occurs in 9-42% of subjects below 
50 years of age who have peripheral or cerebral occlusive arterial 
disease, myocardial infarction, or thromboembolism [23]. About 21% 
of young patients with coronary artery disease, 24% of patients with 
cerebrovascular disease, and 32% of patients with peripheral vascular 
disease are found to have mild postmethionine homocysteinemia.
BETAINE TREATMENT
By ingesting a combination of vitamin B-6, folic acid, and betaine [22] 
or betaine (1.5-6 g/d) [18] alone can be the immediate treatment to 
reduce mild homocysteinemia. Betaine, but not folic acid, is effective 
at preventing an elevated level of postmethionine homocysteine 
concentrations [18]. In the liver and kidney, betaine-dependent 
remethylation occurs. In most cells, folate-dependent remethylation 
occurs. Serum homocysteine concentrations may be represented by 
the extrahepatic supply to the liver through folatere methylation and 
by the hepatic output through betaine remethylation [18]. Therefore, 
combined ingestion of folic acid and betaine may be the most effective 
method of lowering homocysteine.
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
NAFLD is a kind of liver disease ranges from hepatic steatosis 
(accumulation of triglyceride inside hepatocytes) to nonalcoholic 
steatohepatitis (NASH) (necrosis and inflammation), with some people 
ultimately progressing to fibrosis and cirrhosis and liver failure. 
Because of its high prevalence in conjunction with obesity, diabetes, and 
insulin resistance, NAFLD is a hepatic manifestation of the metabolic 
syndrome and denotes an important cause of liver-related morbidity 
and mortality [24].
NAFLD is characterized by insulin resistance and dysregulated 
adipokine production, which is the central mechanism found in the 
development of steatosis and the transitional process to steatohepatitis 
in NAFLD [25]. Accumulation of fat in the liver leads to the imbalance 
in the uptake, synthesis, export, and oxidation of fatty acids. Adipose 
tissue is an important depot in the body to eliminate nonesterified free 
fatty acids.
NASH
NASH, a subtype of NAFLD, results in cirrhosis. In the US, NASH is 
an important cause of liver transplantation. Patient with obesity, 
diabetes, or hyperlipidemia NASH is commonly occurs. Frequently, 
the disease is discovered incidentally with asymptomatic elevation of 
liver aminotransferases on routine laboratory studies, or hepatomegaly 
on examination [26]. NASH has been described as an indolent disease 
leading to progressive fibrosis or cirrhosis in up to 30% of patients and 
is a cause of some cases of “cryptogenic” cirrhosis [27].
BETAINE TREATMENT
Betaine, a naturally occurring dietary compound, is synthesized in vivo 
from the oxidation of choline, and has several effects that may impact 
the natural history of NASH. These include:
1. It acts as a major role as a methyl donor in the conversion of 
homocysteine to methionine
2. Direct substitution for SAM for the direct methylation of 
phosphatidylethanolamine to phosphatidylcholine
3. Its downstream effects on oxidative stress and transsulfuration 
reactions
4. It involves in the activation of adenosine monophosphate activated 
protein kinase
5. Its properties as a lipotrope and osmolyte.
As a naturally acting agent, side effects with betaine would be expected 
to be minimal; however, it depends on the type of administration of 
betaine, as betaine anhydrous oral solution or as capsules. Betaine is 
a nature component of many foods and safe in doses ranging from 3 
to 30 g/day; whereas other insulin sensitizers possess potential side 
effects, betaine may represent an ideal therapeutic agent for NAFLD 
(Table 2).
BETAINE SUPPLEMENTATION
The Indian definition for the dietary supplements as per the Food Safety 
and Security Act 2006 list down the ingredients that a product should 
have and it also specifies general properties of nutraceuticals [28].
• Betaine can be taken in supplement form or derived from food.
• The alcohol-induced fatty liver disease patients are suggested to take 
betaine normally between 1000 and 2000 mg, three times daily. It is 
needed to repair liver damage in certain cases, like with recovering 
alcoholics.
• People can use lower dose of betaine for nutritional support.
• Betaine HCL supplements are help in digestion that are available on 
the market. The suggested dose of betaine is between 650 and 2500 
mg.
• People who want to develop their exercise performance, to increase 
their body composition, to get relief from body aches and pains may 
take between 1500 and 2000 mg of betaine.
CONCLUSION
In the last decade, there has been growing interest in searching for 
cancer prophylactic and therapeutic effects of natural compounds. 
Many in vitro and some in vivo studies confirmed that betaine displayed 
a range of anticancer actions, such as inhibit carcinogen activation, 
cancer cell proliferation, angiogenesis, and metastasis. This review 
focused on unraveling the chemopreventive and therapeutic action 
of betaine and deciphered its molecular targets on human’s different 
carcinoma cells, liver diseases, and other inherited disorders. The 
results showed that betaine exhibits tumoricidal effects and acts as a 
Table 2: Betaine treatment in other diseases
Disease Clinical changes Risk factors Betaine treatment
Homocysteinemia Elevated homocysteine concentration Risk of cardiovascular disease Betaine intake decreases homocysteine 
concentration
Homocystinuria Accumulation of homocysteine in 
blood and urine
Lack of cystathionine 
B-synthase enzyme
Betaine improves 
homocysteineremethylation; lowers plasma 
homocysteine
Mild homocysteinemia Mildly elevated post methionine 
homocysteine concentration
Affects patients with 
peripheral vascular disease
Betaine dependent remethylation occurs
NASH Elevation of liver amino transferases Cirrhosis, liver failure Acts as methyl donor and it involves in the 
activation of AMP activated protein kinase
NASH: Nonalcoholic steato hepatitis, AMP: Adenosine monophosphate
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biological response modifier in cancer treatment by inducing apoptosis 
and cell cycle arrest in a dose- and time-dependent manner. In initial 
stages, it inhibits metabolic activation of carcinogens. In progression 
phases, it induces apoptosis, inhibits cancer cell proliferation and tumor 
metastasis. Many results provide new insights that betaine may serve 
as an alternative approach for cancer prevention and other disorders.
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